What Frazier Life Sciences does

Frazier Life Sciences (legal entity: Frazier Life Sciences Management, L.P.) is a privately held, Palo Alto–headquartered biotech investment firm operating two integrated strategies under one roof: a venture capital strategy focused on early-stage private biopharmaceutical companies (>$4B AUM as of December 31, 2025) and a long-only, evergreen public equity strategy focused on small and mid-cap public biopharmaceuticals and crossover rounds (>$2.8B AUM as of December 31, 2025). Across both strategies the firm manages more than $5B in assets, drawing capital from institutional Limited Partners.

The firm’s core activity is company creation and structured private investment across therapeutic areas (oncology, autoimmune, CNS, ophthalmology, vaccines, orphan diseases, respiratory, cardiometabolic) and modalities (small molecules, biologics, ADCs, gene therapy, cell therapy, radiopharmaceuticals). Its venture team has created 25+ companies since 2015 via spin-outs and de novo formation — examples include Radionetics Oncology (co-created with 5AM Ventures and Crinetics in 2021), Attovia Therapeutics (launched with Alamar Biosciences in 2023), AirNexis Therapeutics (2026 launch with $200M Series A), and GondolaBio (with BridgeBio). The firm also participates in Series A/B/C rounds, often as lead investor, and supports IPOs and de-SPAC transitions (e.g., the Frazier Lifesciences Acquisition Company/FLAC that merged with NewAmsterdam Pharma in 2022 to create NASDAQ: NAMS). Portfolio exits include Alpine Immune Sciences (acquired by Vertex for $4.9B in 2024) and Krystal Biotech (public market support since IPO). The cross-fund venture/public architecture enables continued PIPE and ATM financing of portfolio companies post-IPO, supported by a 15+ person investment team of MDs/PhDs led by Managing Partner Albert Cha.

The firm earns revenue through two primary streams: (i) recurring management fees on committed and invested fund capital from Limited Partners — fee rates are not publicly disclosed — and (ii) carried interest/performance fees on successful exits, which are episodic and tied to realized gains across the venture and public portfolios. The firm has offices in Palo Alto (headquarters), San Diego, Boston, and Seattle (opened February 2026), and is privately held with no parent company or public listing.

Name

Frazier Life Sciences

Legal name

Frazier Life Sciences Management, L.P.

Website

https://frazierls.com

Company type

Private

Founded year

2015

Operating status

Operating

Headcount range

11–50 employees

Short description

Frazier Life Sciences is a privately held biotech investment firm managing more than $5B across integrated venture and public equity strategies, partnering with and building companies developing novel therapeutics from seed through IPO.

Ownership category

akta.pro rank

Product category

Biotech Investment Management

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Investment Advice (6282)

akta.pro primary industry

Healthcare & Life Sciences Growth Equity (FSANACAB)

akta.pro secondary industry

Early-Stage Venture Capital (Series A/B) (FSANAAAB)

Keywords

• Biotech venture capital
• Life sciences investing
• Biopharmaceutical investments
• Company creation
• Public equity strategy

Headquarters

HQ city

Palo Alto

HQ country

United States

HQ region

North America

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Infrastructure, Marketing or Sales

Revenue model

1. Management Fees: Frazier Life Sciences earns management fees from investors (Limited Partners) in its venture and public equity funds. The firm manages over $4B in venture capital AUM and over $2.8B in public equity AUM (as of December 31, 2025).
2. Carried Interest / Performance Fees: As a venture capital and public equity firm, FLS earns carried interest and/or performance fees on successful investments. The firm's venture strategy generated over $75B in cumulative IPO/M&A transaction value since 2015, providing upside on successful exits.
3. Venture Fund Capital Raises: FLS closed an oversubscribed $1.3 billion venture fund in July 2025, representing the firm's primary vehicle for deploying capital into early-stage private biopharmaceutical companies through company creation and Series A/B/C investments.

Go-to-market motion3 records

Core offering

Frazier Life Sciences is a private biotech investment firm that manages dedicated venture capital and public equity strategies focused on biopharmaceutical companies. The venture strategy creates and builds early-stage private companies and leads Series A/B/C financings, while the public equity strategy invests in small and mid-cap public biopharmaceutical companies and crossover rounds. The firm manages more than $5 billion in combined assets under management across both strategies.

Product overview

Frazier Life Sciences (FLS) is a longstanding biotech investment firm rather than a traditional software product company. Its offering is a platform-plus-strategies architecture composed of two core strategies: the Venture Capital Strategy (over $4B AUM, focused on early-stage private biopharmaceutical companies, company creation, and Series A investments) and the Public Equity Strategy (over $2.8B AUM, focused on small and mid-cap public biopharmas and crossover rounds). These strategies are complemented by the Frazier Life Sciences Acquisition Company (FLAC), a former Frazier-sponsored SPAC that merged with NewAmsterdam Pharma in 2022 to create NewAmsterdam Pharma (NASDAQ: NAMS). The portfolio spans a wide range of therapeutic areas (oncology, autoimmune, CNS, vaccines, ophthalmology, orphan diseases, etc.) and modalities (small molecules, biologics, ADCs, cell therapy, gene therapy, radiopharmaceuticals) across dozens of named portfolio companies such as Krystal Biotech, Alpine Immune Sciences, Arcutis Biotherapeutics, Halda Therapeutics, and BridgeBio.

Differentiator

Problem solved

Functional benefit

Products and services

• Frazier Life Sciences Venture Capital Strategy
• Frazier Life Sciences Public Equity Strategy

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration2 records

Feature3 records

Recent moves7 records

Expansion highlights5 records

Direct peers

• OrbiMed: Healthcare-dedicated investment firm spanning venture, growth, and public equity strategies. Comparable to FLS's integrated venture-and-public approach, though with significantly larger AUM.
• Atlas Venture: Early-stage biotech venture firm that builds companies around novel science, comparable in size and strategy to Frazier's venture arm. Both employ a company-creation model and operate from major US biotech hubs.
• Baker Bros. Advisors: Biotech-focused long-only advisor investing across public and private companies. Comparable to Frazier's integrated public/venture model with deep sector specialization.
• ARCH Venture Partners: One of the largest US biotech-focused venture firms, originating and co-creating companies across modalities and stages. Comparable to FLS in company-creation approach and life-sciences specialization, with a broader AUM base.
• 5AM Ventures: Biotech-focused early-stage venture capital firm that co-led Radionetics Oncology with Frazier Life Sciences. Directly comparable as a co-creation partner in company formation, with similar AUM scale and a focus on translational science.
• RA Capital Management: Crossover healthcare investor operating public and private strategies, frequently co-investing in Series A rounds alongside FLS. Similar domain specialization and stage coverage makes it a direct competitor for biotech mandates.
• Versant Ventures: Healthcare-dedicated venture firm with a comparable company-creation approach (e.g., Inception Therapeutics). Similar AUM scale and stage focus to FLS, making it a close peer for LP benchmarking and deal co-investment.

Broad incumbents

• New Enterprise Associates (NEA): Large diversified venture firm with a dedicated healthcare practice that invests across biotech stages. Comparable in venture stage focus but operates a much broader multi-sector platform than FLS's life-sciences-only mandate.
• Deerfield Management: Healthcare-dedicated investment manager with venture, public, and private credit strategies. Comparable domain focus but materially larger and more diversified than Frazier's pure-play biotech platform.

Emerging players

• venBio Partners: Biotech-focused venture firm investing in therapeutic platforms with company-creation elements. Comparable strategic approach but typically at smaller check sizes and lower AUM than FLS.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/frazier-life-sciences

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles10 records

Subsidiaries3 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments20 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Frazier Life Sciences